Neuroleptic Malignant Syndrome due to Atypical Neuroleptics: Three Episodes in One Patient

Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication of antipsychotic medication. The risk of developing NMS under atypical neuroleptics seems lower than under typical neuroleptics. However, the use of atypical neuroleptics in modern psychopharmacotherapy is increasing, so the incidence of NMS under these drugs may also increase. Here, we will describe three episodes of NMS that fulfilled the DSM-IV criteria for NMS (APA, 1994). The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride. These episodes had some atypical features that will be discussed with regard to the pathophysiological mechanisms leading to NMS.

References

• 1 Addonizio G, Susman V L, Roth S D. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients.  Am J Psychiatry. 1986;  143 1587-1590
• 2 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington D.C. 1994
• 3 Anderson E S, Powers P S. Neuroleptic malignant Syndrome Associated With Clozapine Use.  J Clin Psychiatry. 1991;  52 102-104
• 4 Bajjoka I, Patel T, O'Sullivan T. Risperidone-induced neuroleptic malignant syndrome.  Ann Emerg Med,. 1997;  30 698-700
• 5 Blumer D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings.  Compr Psychiatry. 1997;  38 (4) 193-201
• 6 Corrigan F M, Coulter F. Neuroleptic malignant syndrome, amitriptyline and thioridazine.  Biol Psychiatry. 1988;  23 320-321
• 7 DasGupta K, Young A. Clozapine-Induced Neuroleptic Malignant Syndrome.  J Clin Psychiatry. 1991;  52 105-107
• 8 Eikmeier G, Muszynski K, Berger M, Gastpar M. High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial.  Pharmacopsychiatry. 1990;  23 (5) 212-214
• 9 Fink M. Toxic Serotonin Syndrome or Neuroleptic Malignant Syndrome.  Pharmacopsychiat. 1996;  29 159-161
• 10 Gurrera R J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome.  Am J Psychiatry. 1999;  156 169-180
• 11 Hegerl U, Bottlender R, Gallinat J. et al . The serotonin syndrome scale: first results on validity.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 96-103
• 12 Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome.  Biol Psychiatry. 1994;  36 781-782
• 13 Karagianis J L, Phillips L C, Hogan K P. et al . Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature.  Ann-Pharmacother. 1999;  33 623-630
• 14 Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T, Sugiyama N, Kosaka K. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.  J Neurol Sci. 1998;  160 (1) 102-104
• 15 Kern J L, Cernek P K. Delayed risperidone-induced neuroleptic malignant syndrome.  Ann Pharmacother. 1996;  30 (3) 300
• 16 Lee M S, Lee H J, Kim L. A case of delayed NMS induced by risperidone.  Psychiatr Serv. 2000;  51 (2) 254-255
• 17 Merriam A E. Withdrawal NMS after drug treatment.  Biol Psychiatry. 1988;  24 (3) 368-369
• 18 Miller D D, Sharafuddin J A, Kathol R G. A Case of Clozapine-Induced Neuroleptic Malignant Syndrome.  J Clin Psychiatry. 1991;  52 99-101
• 19 Miyaoka H, Kamijima K. Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?.  Int Clin Psychopharmacol. 1995;  10 265-267
• 20 Newman M, Adityanjee , Jampala C. Atypical neuroleptic malignant syndrome associated with risperidon treatment (letter).  Am J Psychiatry. 1997;  154 1475
• 21 Pope H G, Keck P E , McElroy S L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.  Am J Psychiatry. 1986;  143 1227-1233
• 22 Ram A, Cao Q, Keck P E, Pope H G, Otani K, Addonizio G, McElroy S L, Kaneko S, Redlichova M, Gershon E S, Gejman P V. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome.  Am J Med Genet. 1995;  60 228-230
• 23 Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment.  Clin Neuropharmacol. 2000;  23 276-280
• 24 Shaley A, Munitz H. The Neuroleptic Malignant Syndrome. Agent and host interaction.  Acta Psychiatr. Scand1986;  73 337
• 25 Sharma R, Trappler B, Ng Y K, Leeman C P. Risperidone-induced neuroleptic malignant syndrome.  Ann Pharmakother. 1996;  30 775-778
• 26 Singer S, Richards C, Boland R J. Two cases of risperidone-induced neuroleptic malignant syndrome (letter).  Am J Psychiatry. 1995;  152 1234
• 27 Spivak B, Weizman A, Wolovick L. et al . Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.  Acta Psychiatr Scand. 1990;  81 168-169
• 28 Stanilla J K, de Leon J, Simpson G M. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases.  J Clin Psychiatry. 1997;  58 252-255
• 29 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713